|
|
|
|
|
|
Sponsors and Collaborators: |
Göteborg University Swedish Cancer Foundation Medical Research Council |
Information provided by: | Göteborg University |
ClinicalTrials.gov Identifier: | NCT00329615 |
The study is designed to evaluate whether daily insulin treatment to weight losing cancer patients attenuates progression of cancer cachexia and improves metabolism.
Condition | Intervention | Phase |
Cancer Cachexia |
Drug: Insulatard, flexpen |
Phase IV |
MedlinePlus related topics: | Cancer |
ChemIDplus related topics: | Insulin |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Insulin Treatment in Cancer Cachexia: Effects on Survival, Metabolism and Physical Functioning. A Randomized Prospective Study. |
Estimated Enrollment: | 135 |
Study Start Date: | January 2000 |
Estimated Study Completion Date: | September 2005 |
Randomized study with long-term follow-up based on survival, health related quality of life, food intake, resting energy expenditure, body composition, exercise capacity and measurement of metabolic efficiency.
Ages Eligible for Study: | 25 Years to 85 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Sweden | |||||
Department of Surgery, Inst of Clinical Sciences | |||||
Göteborg, Sweden, SE413 45 |
Göteborg University |
Swedish Cancer Foundation |
Medical Research Council |
Principal Investigator: | Kent G Lundholm, MD | Department of Surgery, Göteborg University |
Study ID Numbers: | kl450112 |
First Received: | May 23, 2006 |
Last Updated: | May 23, 2006 |
ClinicalTrials.gov Identifier: | NCT00329615 |
Health Authority: | Sweden: Medical Products Agency |
|
|
|